MAIA Takes Aim at a $50B Immunotherapy Market with Breakthrough Telomere-Targeting Approach
MAIACHICAGO, Dec. 10, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology (NYSE American: MAIA) – The treatment paradigm for advanced non-small cell lung cancer (NSCLC) is undergoing another shift. After a decade of targeted therapies and checkpoint inhibitors (CPIs) dominating headlines, MAIA believes that a new therapeutic class—telomere-targeting agents—is emerging for the population with substantial unmet medical need: patients without actionable mutations and who no longer respond to CPIs or chemotherapy.
MAIA Biotechnology Announces Open Market Purchases by CEO and Directors
MAIACHICAGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the CEO and certain members of the Company’s Board of Directors purchased approximately 182,445 shares of MAIA common stock at market price between November 21 and 28, 2025. The average common stock price was $1.06.
MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer
MAIA(MAIA) CHICAGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today highlighted positive efficacy data from its Phase 2 clinical trial, THIO-101, evaluating ateganosine (THIO) sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who had failed two or more standard-of-care therapy regimens.
MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells
MAIACHICAGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that a manuscript detailing developments in its Phase 2 THIO-101 clinical trial was accepted and published in the international peer-reviewed open access scientific journal, Cells, in a special issue, “Cellular Mechanisms of Anti-Cancer Therapies”
MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies
MAIACHICAGO--(BUSINESS WIRE)--MAIA Biotechnology Announces Master Clinical Supply Agreement with Roche for Hard-to-Treat Cancer Therapies
MAIA Biotechnology to Present at BIO International Convention 2025
MAIACHICAGO--(BUSINESS WIRE)--MAIA Biotechnology to Present at BIO International Convention 2025
MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients
MAIAMAIA posts 17.8-month median survival in NSCLC trial, nearly tripling standard care; long-term response seen in a chemo- and immunotherapy-resistant group.
MAIA Biotechnology Says New Partial Response Identified In Patient After 20 Months Of Treatment In Phase 2 THIO-101 Clinical Trial Evaluating Ateganosine, Sequenced With Regeneron's Immune CPI Libtayo In NSCLC Patients
MAIAMAIA Biotechnology Reports Updated Phase 2 THIO-101 Trial Data Showing Median Overall Survival Of 17.8 Months With Ateganosine Plus Cemiplimab In Heavily Pre-Treated NSCLC Patients
MAIAMAIA Biotechnology Announces Private Placement of 446,332 Shares At $1.50/Shr
MAIAMAIA Biotechnology Announces That An Abstract About The Efficacy Data From The Phase 2 THIO-101 Clinical Trial Was Accepted For Poster Presentation At The 2025 Annual Meeting Of The ASCO, Taking Place May 30 To June 3, 2025
MAIAMAIA Biotechnology Announces $1.08M Private Placement Of 719,999 Shares At $1.50/Share
MAIAMAIA Biotechnology Announces The Publication Of Preclinical Data For Its Lead Proprietary Telomere-Targeting THIO Dimer In The Peer-Reviewed Scientific Journal Naunyn-Schmiedeberg's Archives Of Pharmacology; Novel THIO Dimer Shows Promise As A New Compoun
MAIAMAIA Biotechnology Announces USAN Approval Of Ateganosine As Generic Name For Lead Molecule THIO, A Telomere-Targeting Anticancer Agent For Advanced NSCLC Treatment In FDA Process
MAIAMAIA Biotechnology To Initiate Phase 3 Pivotal Trial Of THIO Sequenced With Checkpoint Inhibitor Compared With Chemotherapy Treatment In Advanced Non-Small Cell Lung Cancer Patients; Phase 3 Trial Is Designed To Provide A Direct Comparison To Chemotherapy
MAIAMAIA Biotechnology Announces Design For Expansion Of THIO-101 Phase 2 Trial In Advanced Non-Small Cell Lung Cancer; To Enroll Patients In The U.S. And Select Countries In Europe And Asia
MAIAMAIA Biotechnology Announces $1.43M Non-Brokered Private Placement Of 952,300 Shares At $1.50/Share
MAIAMAIA Biotechnology Announces $2.715M Private Placement Of 1.81M Shares Of Common Stock At A Purchase Price Of $1.50 Per Share
MAIAMAIA Biotechnology To Present Late-Breaking THIO-101 Phase 2 Trial Updates On THIO And Cemiplimab Combo In NSCLC At SITC 2024, Highlighting Long-Term Therapeutic Benefits Beyond Treatment Cessation
MAIAMAIA Biotechnology TO Present At BIO International Convention 2024
MAIA